Please assess the completion status of the following clinical trial:

Trial Title: Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* documented HIV infection~* age of at least 18 years old~* HIV viral load \<400 on the most recent test~Exclusion Criteria:~* current acute moderate to severe illness (demonstrated by fever over 100.4 Fahrenheit, shortness of breath, altered mental status, or by judgment of the primary clinician)~* current pregnancy~* history of allergic reaction to a polio shot,~* history of a life-threatening allergic reaction to neomycin, streptomycin, or polymyxin B

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 2/5 dose intradermal IPV (Type: EXPERIMENTAL): Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
- 1/5 dose intradermal IPV (Type: EXPERIMENTAL): Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
- full dose intramuscular IPV (Type: ACTIVE_COMPARATOR): Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
- 2/5 dose intramuscular IPV (Type: ACTIVE_COMPARATOR): Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.

Based on this trial design, predict the completion outcome and termination type (if applicable).